DK1400518T3 - Heterocycliske forbindelser og lægemidler - Google Patents

Heterocycliske forbindelser og lægemidler

Info

Publication number
DK1400518T3
DK1400518T3 DK02722772T DK02722772T DK1400518T3 DK 1400518 T3 DK1400518 T3 DK 1400518T3 DK 02722772 T DK02722772 T DK 02722772T DK 02722772 T DK02722772 T DK 02722772T DK 1400518 T3 DK1400518 T3 DK 1400518T3
Authority
DK
Denmark
Prior art keywords
drugs
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
DK02722772T
Other languages
Danish (da)
English (en)
Inventor
Tetsuo Asaki
Taisuke Hamamoto
Keiichi Kuwano
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18978246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1400518(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of DK1400518T3 publication Critical patent/DK1400518T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK02722772T 2001-04-26 2002-04-25 Heterocycliske forbindelser og lægemidler DK1400518T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001129765 2001-04-26
PCT/JP2002/004118 WO2002088084A1 (fr) 2001-04-26 2002-04-25 Derives de composes heterocycliques et medicaments

Publications (1)

Publication Number Publication Date
DK1400518T3 true DK1400518T3 (da) 2007-03-26

Family

ID=18978246

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02722772T DK1400518T3 (da) 2001-04-26 2002-04-25 Heterocycliske forbindelser og lægemidler

Country Status (19)

Country Link
US (1) US7205302B2 (fr)
EP (1) EP1400518B1 (fr)
JP (1) JP4479152B2 (fr)
KR (1) KR100921760B1 (fr)
CN (1) CN1301973C (fr)
BE (1) BE2016C051I2 (fr)
BR (1) BRPI0209249B8 (fr)
CA (1) CA2445344C (fr)
DE (1) DE60217674T2 (fr)
DK (1) DK1400518T3 (fr)
ES (1) ES2276931T3 (fr)
FR (1) FR16C0042I2 (fr)
LU (1) LU93266I2 (fr)
MX (1) MXPA03009800A (fr)
NL (1) NL300836I2 (fr)
PT (1) PT1400518E (fr)
RU (1) RU2283835C3 (fr)
TW (1) TWI316055B (fr)
WO (1) WO2002088084A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005037199A2 (fr) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide
FR2869224B1 (fr) * 2004-04-22 2006-06-09 Oreal Compose 2-oxy-acetamide, ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
WO2005107687A1 (fr) * 2004-04-22 2005-11-17 L'oreal Compose 2-oxy-acetamide ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
DK2246336T3 (da) * 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
ES2875944T3 (es) * 2008-03-18 2021-11-11 Arena Pharm Inc Moduladores del receptor de prostaciclina (PG12) útiles para el tratamiento de trastornos relacionados con el mismo
WO2009154246A1 (fr) * 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
CN102065864B (zh) * 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157396A1 (fr) * 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour la sténose du canal spinal
WO2009157397A1 (fr) * 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
MY163762A (en) 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
NO2315587T3 (fr) * 2008-08-13 2018-03-24
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (fr) * 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
TWI513462B (zh) 2009-11-13 2015-12-21 Toray Industries 糖尿病之治療或預防藥
DK2531492T3 (en) 2010-02-05 2016-07-04 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivatives
SI2593452T1 (sl) 2010-07-14 2017-06-30 Novartis Ag Heterociklične spojine agonisti receptorja IP
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
JP6121339B2 (ja) 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
WO2014125413A1 (fr) 2013-02-13 2014-08-21 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
WO2015056504A1 (fr) 2013-10-15 2015-04-23 小野薬品工業株式会社 Greffe d'endoprothèse à élution de médicament
CN103588598B (zh) * 2013-11-20 2015-06-17 苏州大学 一种制备2-烯醛衍生物的方法
CN104829465B (zh) 2015-02-13 2018-04-27 普济生物科技（台州）有限公司 一种4-异丙氨基-1-丁醇的制备方法
CN106279047B (zh) 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (fr) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Selexipag amorphe et son procédé de préparation
CN106467496B (zh) * 2015-08-14 2020-12-08 苏州国匡医药科技有限公司 4-[(5,6-二苯基哌嗪-2-基)(异丙基)胺基]-1-丁醇的制备方法
EP3344607B1 (fr) 2015-09-03 2019-11-06 Teva Pharmaceuticals International GmbH Formes à l'état solide de selexipag
WO2017042828A2 (fr) 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Procédé de préparation de sélexipag et intermédiaires de ce dernier
WO2017042731A1 (fr) 2015-09-10 2017-03-16 Lupin Limited Forme amorphe du sélexipag et dispersion solide associée
WO2017060827A1 (fr) 2015-10-07 2017-04-13 Lupin Limited Procédé amélioré pour la préparation de sélexipag ou de ses sels pharmaceutiquement acceptables
AU2016366073B2 (en) * 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
WO2017109772A1 (fr) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Forme amorphe du sélexipag
CN107108429B (zh) 2015-12-23 2022-08-19 联邦科学与工业研究组织 化合物
EP3192502A1 (fr) 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag
ES2911531T3 (es) * 2016-04-01 2022-05-19 Honour R&D Procedimiento para la preparación de los derivados de difenilpirazina
CN107286104A (zh) * 2016-04-12 2017-10-24 常州方楠医药技术有限公司 一种赛乐西帕与药用辅料的固体分散体及其制备方法
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
EP3481807A4 (fr) * 2016-07-05 2020-01-15 Maithri Drugs Private Limited Nouveau procédé de préparation de 2-{4-[(5,6-diphényl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(méthylsulfonyl)acétamide et nouveaux polymorphes associés
WO2018015974A1 (fr) 2016-07-20 2018-01-25 Mylan Laboratories Limited Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag
WO2018015975A1 (fr) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Dispersion solide amorphe de selxipag.
WO2018022704A1 (fr) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Forme cristalline vi de selexipag
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
EP3495348A4 (fr) 2016-07-29 2020-01-22 Toray Industries, Inc. Dérivé de guanidine et son utilisation à des fins médicales
CN106316967B (zh) * 2016-08-19 2019-02-05 上海艾康睿医药科技有限公司 西里帕格中间体及西里帕格的制备方法
WO2018078383A1 (fr) 2016-10-27 2018-05-03 Cipla Limited Composition pharmaceutique comprenant du selexipag amorphe
CA3046025A1 (fr) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Procedes et compositions de traitement de l'hypertension pulmonaire et d'autres troubles des poumons
AU2018227842B2 (en) 2017-03-01 2024-05-02 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN107365275B (zh) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 高纯度的赛乐西帕
EP3658187A1 (fr) 2017-07-27 2020-06-03 Allergan, Inc. Agonistes du récepteur de la prostacycline pour la réduction de la graisse corporelle
TWI801421B (zh) * 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
BR112020008940A2 (pt) 2017-11-16 2020-10-20 Nippon Shinyaku Co., Ltd. preparação de liberação controlada
JP2021512902A (ja) * 2018-02-07 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド プロスタサイクリン受容体アゴニスト
US20200397700A1 (en) 2018-02-21 2020-12-24 Nippon Shinyaku Co., Ltd. Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
CN108558653A (zh) * 2018-05-14 2018-09-21 湖南华腾制药有限公司 赛乐西帕中间体及赛乐西帕的制备方法
CN108774183A (zh) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 一种乙二醇类化合物的制备方法
CN108863955B (zh) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 二苯基吡嗪类化合物或其药学上可接受的盐、异构体及其制备方法和用途
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
JP2022532076A (ja) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
JP2022533394A (ja) 2019-05-21 2022-07-22 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療を受けている患者のセレキシパグへの移行方法
US20220323437A1 (en) 2019-06-11 2022-10-13 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
TW202114998A (zh) * 2019-08-19 2021-04-16 日商日本新藥股份有限公司 鹽
CA3154802A1 (fr) 2019-10-23 2021-04-29 Marc Patrik SCHRADER Composition pharmaceutique comprenant du selexipag
JP2023504115A (ja) 2019-11-29 2023-02-01 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
WO2021152060A1 (fr) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Composition de sélexipag à libération contrôlée
EP4100013A1 (fr) 2020-02-03 2022-12-14 Actelion Pharmaceuticals Ltd Méthodes de traitement et d'évaluation de l'hypertension artérielle pulmonaire au moyen de sélexipag
WO2022106621A1 (fr) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Sélexipag destiné à être utilisé par l'intermédiaire d'une administration intracôlon
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
WO2022211052A1 (fr) 2021-03-31 2022-10-06 日本新薬株式会社 Agent thérapeutique contre un trouble de la marche
JP7010404B1 (ja) 2021-03-31 2022-02-10 日本新薬株式会社 歩行障害治療剤
WO2022238375A1 (fr) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Méthodes de traitement de l'hypertension pulmonaire
CN118146165A (zh) * 2021-11-29 2024-06-07 郑州大学 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
IL314717A (en) 2022-02-15 2024-10-01 United Therapeutics Corp Crystalline prostacyclin (IP) receptor agonist and uses thereof
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024131672A1 (fr) * 2022-12-20 2024-06-27 长风药业股份有限公司 Dérivé de diphényl pyrazine, son procédé de préparation et son utilisation
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
WO2024194449A1 (fr) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant un dérivé de diphénylpyrazine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2821381A1 (de) 1977-05-17 1978-11-30 Diamond Shamrock Corp Substituierte 1,2,4-triazine und sie enthaltende pharmazeutische zubereitungen
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
US5219510A (en) * 1990-09-26 1993-06-15 Eastman Kodak Company Method of manufacture of cellulose ester film
JP3169413B2 (ja) 1992-01-31 2001-05-28 エーザイ株式会社 イミダゾール誘導体
JPH0733752A (ja) 1993-07-16 1995-02-03 Sankyo Co Ltd ジフェニルピラジン誘導体及び除草剤
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist

Also Published As

Publication number Publication date
JPWO2002088084A1 (ja) 2004-09-09
JP4479152B2 (ja) 2010-06-09
WO2002088084A1 (fr) 2002-11-07
EP1400518A4 (fr) 2005-04-20
CN1301973C (zh) 2007-02-28
LU93266I2 (fr) 2016-12-19
TWI316055B (fr) 2009-10-21
DE60217674D1 (de) 2007-03-08
FR16C0042I2 (fr) 2017-03-17
EP1400518A1 (fr) 2004-03-24
US20040102436A1 (en) 2004-05-27
EP1400518B1 (fr) 2007-01-17
KR20040015174A (ko) 2004-02-18
BR0209249A (pt) 2004-06-08
BE2016C051I2 (fr) 2021-07-19
KR100921760B1 (ko) 2009-10-15
ES2276931T3 (es) 2007-07-01
DE60217674T2 (de) 2007-10-11
CN1516690A (zh) 2004-07-28
RU2283835C3 (ru) 2021-02-15
CA2445344C (fr) 2011-07-26
BRPI0209249B8 (pt) 2021-05-25
PT1400518E (pt) 2007-03-30
FR16C0042I1 (fr) 2016-12-09
NL300836I2 (fr) 2016-11-16
RU2283835C2 (ru) 2006-09-20
US7205302B2 (en) 2007-04-17
MXPA03009800A (es) 2004-01-29
RU2003134190A (ru) 2005-06-10
CA2445344A1 (fr) 2002-11-07
BRPI0209249B1 (pt) 2016-04-26

Similar Documents

Publication Publication Date Title
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
NO20041975D0 (no) Bicyklisk oksopyridin og oksopyrimidinderivater
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
NO20033203L (no) Terapeutiske heterocykliske forbindelser
NO20016314D0 (no) Blandinger og fremgangsmåte for oljefeltapplikasjoner
NO20024874L (no) Benzoamidpiperidin-inneholdende forbindelser og beslektede forbindelser
NO20043733L (no) Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20024355L (no) Nukleosidforbindelser og anvendelser derav
EE200300416A (et) Ravimvorm
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20035315D0 (no) Farmasöytiske kombinasjoner
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
DE60232445D1 (de) Cetirizin und pseudoephedrin enthaltende tablette
IS6752A (is) Afleiður tryptamíns og hliðstæð efnasambönd ásamtlyfjaforskriftum þeirra
NO20035331D0 (no) Nye heterocyklisk forbindelse og medisinsk anvendelse derav
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
NO20034172D0 (no) Bisykliske guanidinderivater og terapeutiske anvendelser derav
NO20034785D0 (no) Farmasöytiske kombinasjoner basert på pyridoindolon-derivater og anticancermidler
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen